PDCD1 and diffuse large B-cell lymphoma: Consistent with the favorable prognostic effect, IGHV-SHMhigh patients had more enriched MHC-II neoantigens with rare neoepitopes by in silico prediction [22] but lower T-cell PD-1 expression in ABC-DLBCL.